Reprogrammed human adult stem cells rescue diseased muscle in mice

Dec 12, 2007

Scientists report that adult stem cells isolated from humans with muscular dystrophy can be genetically corrected and used to induce functional improvement when transplanted into a mouse model of the disease. The research, published by Cell Press in the December issue of Cell Stem Cell, represents a significant advance toward the future development of a gene therapy that uses a patient’s own cells to treat this devastating muscle-wasting disease.

Duchenne muscular dystrophy (DMD) is a hereditary disease caused by a mutation in the gene that codes for a muscle protein called dystrophin. Dystrophin is a key structural protein that helps to keep muscle cells intact. DMD is characterized by a chronic degeneration of skeletal muscle cells that leads to progressive muscle weakness. Although intense research has focused on finding a way to replace the defective dystrophin protein, at this time there is no cure for DMD.

A research group led by Dr. Yvan Torrente from the University of Milan used a combination of cell- and gene-based therapy to isolate adult human stem cells from DMD patients and engineer a genetic modification to correct the dystrophin gene. “Use of the patient’s own cells would reduce the risk of implant rejection seen with transplantation of normal muscle-forming cells,” explains Dr. Torrente.

Muscle stem cells, identified by expression of the CD133 surface marker, were isolated from normal and dystrophic human blood and skeletal muscle. The isolated human muscle progenitors were implanted into the muscles of mice and were successfully recruited into muscle fibers. As expected, the CD133+ cells isolated from DMD patients expressed the mutated gene for dystrophin and gave rise to muscle cells that resembled muscle fibers in DMD patients.

The researchers then used a sophisticated genetic technique to repair the mutated dystrophin gene in the isolated DMD CD133+ cells so that dystrophin synthesis was restored. Importantly, intramuscular or intra-arterial delivery of the genetically corrected muscle cell progenitors resulted in significant recovery of muscle morphology, function, and dystrophin expression in a mouse model of muscular dystrophy.

“These data demonstrate that genetically engineered blood or muscle-derived CD133+ cells represent a possible tool for future stem cell-based autograft applications in humans with DMD,” says Dr. Torrente. The authors caution that significant additional work needs to be done prior to using this technology in humans. “Additional research will substantially enhance our understanding of the mechanisms underlying this effect and may lead to the improvement of gene and cell therapy strategies for DMD.”

Source: Cell Press

Explore further: Study on pesticides in lab rat feed causes a stir

Related Stories

Pig stress syndrome linked to gene defect

Apr 30, 2013

Undergoing surgery, even a minor procedure, can be stressful for anyone. But for people who have malignant hyperthermia, a hereditary disease that's triggered by certain drugs used for general anesthesia, ...

Recommended for you

Cuban, US scientists bond over big sharks

1 hour ago

Somewhere in the North Atlantic right now, a longfin mako shark—a cousin of the storied great white—is cruising around, oblivious to the yellow satellite tag on its dorsal fin.

Seafaring spiders depend on their 'sails' and 'anchors'

2 hours ago

Spiders travel across water like ships, using their legs as sails and their silk as an anchor, according to research published in the open access journal BMC Evolutionary Biology. The study helps explain how sp ...

Stopping Candida in its tracks

2 hours ago

Scientists are one step closer to understanding how a normally harmless fungus changes to become a deadly infectious agent.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.